Enhancing Treatment of Hepatitis C in Opioid Substitution Settings II (ETHOS II): A Partnership Project to Enhance Hepatitis C Care in Drug and Alcohol Clinics
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 6,000
- 试验地点
- 61
- 主要终点
- Number of participants commencing anti-HCV treatment
研究概览
简要总结
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.
详细描述
The ETHOS II Project is a collaborative research project led by the Kirby Institute, UNSW Sydney, in partnership with:
- The Centre for Social Research in Health, UNSW Sydney
- NSW Health
- NSW Users and AIDS Association
- Hepatitis NSW
- Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM)
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.
The ETHOS II Project is divided into three parts:
I. ETHOS ENGAGE cohort; II. Qualitative research on barriers/facilitators to HCV care; III. HCV toolkit, education and training.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participant has voluntarily signed the informed consent form;
- •18 years of age or older;
- •History of injecting drug use*;
- •Recent injecting drug use (previous six months) or currently receiving OST*.
- •These criteria will not apply for recruitment from residential rehabilitation centres
排除标准
- 未提供
研究组 & 干预措施
Campaign Days
All participants have the intervention of the campaign days which include hepatitis C screening, fibroscans and clinical assessments.
干预措施: Campaign days (Procedure)
结局指标
主要结局
Number of participants commencing anti-HCV treatment
时间窗: Every year post enrolment for up to 3 years
Evaluation of number of participants commencing anti-HCV treatment
次要结局
未报告次要终点